DHI Group, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 4, 2026
During J. P. Morgan Healthcare Week, Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma Partners and Media [Yahoo! Finance]
BioSpace Names 15 Top Startups to Watch in 2026 [Yahoo! Finance]
FDA Announcements Spark Vigorous Debate, Controversy [Forbes]
DHI Group (NYSE:DHX) had its "hold" rating reaffirmed by analysts at Lake Street Capital. They now have a $2.50 price target on the stock, down previously from $3.00.